335 related articles for article (PubMed ID: 26623049)
1. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
Osumi H; Shinozaki E; Osako M; Kawazoe Y; Oba M; Misaka T; Goto T; Kamo H; Suenaga M; Kumekawa Y; Ogura M; Ozaka M; Matsusaka S; Chin K; Hatake K; Mizunuma N
Mol Clin Oncol; 2015 Sep; 3(5):1053-1057. PubMed ID: 26623049
[TBL] [Abstract][Full Text] [Related]
2. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
[TBL] [Abstract][Full Text] [Related]
3. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
4. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S; Chantrill LA; Pavlakis N; Khasraw M; Underhill C; Ciardiello F; Jefford M; Wasan H; Haydon A; Price TJ; van Hazel G; Wilson K; Simes J; Shapiro JD
J Clin Oncol; 2016 Jul; 34(19):2258-64. PubMed ID: 27114605
[TBL] [Abstract][Full Text] [Related]
5. Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab.
Tural D; Selcukbiricik F; Erdamar S; Ozkurt CU; Yanmaz T; Mandel NM; Serdengeçti S
Hepatogastroenterology; 2013; 60(125):1035-40. PubMed ID: 23537520
[TBL] [Abstract][Full Text] [Related]
6. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
[TBL] [Abstract][Full Text] [Related]
7. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
[TBL] [Abstract][Full Text] [Related]
8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Eur J Cancer; 2016 Mar; 55():122-30. PubMed ID: 26812186
[TBL] [Abstract][Full Text] [Related]
10. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis.
Lin LI; Chen LL; Wang Y; Meng XY; Liang C; Zhou FX
Mol Clin Oncol; 2016 Jun; 4(6):1017-1024. PubMed ID: 27284437
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
Nakamura M; Aoyama T; Ishibashi K; Tsuji A; Takinishi Y; Shindo Y; Sakamoto J; Oba K; Mishima H
Cancer Chemother Pharmacol; 2017 Jan; 79(1):29-36. PubMed ID: 27878354
[TBL] [Abstract][Full Text] [Related]
14. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
[TBL] [Abstract][Full Text] [Related]
15. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
16. KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.
Kumar SS; Price TJ; Mohyieldin O; Borg M; Townsend A; Hardingham JE
Gastrointest Cancer Res; 2014 Jan; 7(1):23-6. PubMed ID: 24558511
[TBL] [Abstract][Full Text] [Related]
17. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
18. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
19. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
